Cargando…

Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study

Objective: In addition to the most common somatic lung cancer mutations (i. e., KRAS and EGFR mutations), other genes may harbor mutations that could be relevant for lung cancer. We defined BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and RET mutations as “niche” mutations and analyzed. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Aramini, Beatrice, Banchelli, Federico, Bettelli, Stefania, Manfredini, Samantha, D’Amico, Roberto, Masciale, Valentina, Pinelli, Massimo, Moretti, Margherita, Stefani, Alessandro, Bertolini, Federica, Dominici, Massimo, Morandi, Uliano, Maiorana, Antonino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007296/
https://www.ncbi.nlm.nih.gov/pubmed/32082488
http://dx.doi.org/10.18632/oncotarget.27472
_version_ 1783495301255921664
author Aramini, Beatrice
Banchelli, Federico
Bettelli, Stefania
Manfredini, Samantha
D’Amico, Roberto
Masciale, Valentina
Pinelli, Massimo
Moretti, Margherita
Stefani, Alessandro
Bertolini, Federica
Dominici, Massimo
Morandi, Uliano
Maiorana, Antonino
author_facet Aramini, Beatrice
Banchelli, Federico
Bettelli, Stefania
Manfredini, Samantha
D’Amico, Roberto
Masciale, Valentina
Pinelli, Massimo
Moretti, Margherita
Stefani, Alessandro
Bertolini, Federica
Dominici, Massimo
Morandi, Uliano
Maiorana, Antonino
author_sort Aramini, Beatrice
collection PubMed
description Objective: In addition to the most common somatic lung cancer mutations (i. e., KRAS and EGFR mutations), other genes may harbor mutations that could be relevant for lung cancer. We defined BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and RET mutations as “niche” mutations and analyzed. The aim of this retrospective cohort study was to assess the differences in the overall survival (OS) of patients with lung adenocarcinoma harboring niche somatic mutations. Results: Data were gathered for 252 patients. Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET. The multivariable analysis showed that 1) niche mutations had a higher mortality than EGFR mutations (HR = 2.3; 95% CI = 1.2–4.4; p = 0.009); 2) KRAS mutations had a higher mortality than EGFR mutations (HR = 2.5; 95% CI = 1.4–4.5; p = 0.003); 3) niche mutations presented a similar mortality to KRAS mutations (HR = 0.9; 95% CI = 0.6–1.5; p = 0.797). Methods: Three cohorts of mutations were selected from patients with lung adenocarcinoma and their OS was compared. Mutations that were searched for, were 1) BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and RET; 2) K-RAS; and 3) EGFR. Differences in OS between these three cohorts were assessed by means of a multivariable Cox model that adjusted for age, sex, smoking habits, clinical stages, and treatments. Conclusions: Niche mutations exhibited an increased risk of death when compared with EGFR mutations and a similar risk of death when compared with KRAS mutations.
format Online
Article
Text
id pubmed-7007296
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-70072962020-02-20 Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study Aramini, Beatrice Banchelli, Federico Bettelli, Stefania Manfredini, Samantha D’Amico, Roberto Masciale, Valentina Pinelli, Massimo Moretti, Margherita Stefani, Alessandro Bertolini, Federica Dominici, Massimo Morandi, Uliano Maiorana, Antonino Oncotarget Research Paper Objective: In addition to the most common somatic lung cancer mutations (i. e., KRAS and EGFR mutations), other genes may harbor mutations that could be relevant for lung cancer. We defined BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and RET mutations as “niche” mutations and analyzed. The aim of this retrospective cohort study was to assess the differences in the overall survival (OS) of patients with lung adenocarcinoma harboring niche somatic mutations. Results: Data were gathered for 252 patients. Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET. The multivariable analysis showed that 1) niche mutations had a higher mortality than EGFR mutations (HR = 2.3; 95% CI = 1.2–4.4; p = 0.009); 2) KRAS mutations had a higher mortality than EGFR mutations (HR = 2.5; 95% CI = 1.4–4.5; p = 0.003); 3) niche mutations presented a similar mortality to KRAS mutations (HR = 0.9; 95% CI = 0.6–1.5; p = 0.797). Methods: Three cohorts of mutations were selected from patients with lung adenocarcinoma and their OS was compared. Mutations that were searched for, were 1) BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and RET; 2) K-RAS; and 3) EGFR. Differences in OS between these three cohorts were assessed by means of a multivariable Cox model that adjusted for age, sex, smoking habits, clinical stages, and treatments. Conclusions: Niche mutations exhibited an increased risk of death when compared with EGFR mutations and a similar risk of death when compared with KRAS mutations. Impact Journals LLC 2020-02-04 /pmc/articles/PMC7007296/ /pubmed/32082488 http://dx.doi.org/10.18632/oncotarget.27472 Text en Copyright: © 2020 Aramini et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Aramini, Beatrice
Banchelli, Federico
Bettelli, Stefania
Manfredini, Samantha
D’Amico, Roberto
Masciale, Valentina
Pinelli, Massimo
Moretti, Margherita
Stefani, Alessandro
Bertolini, Federica
Dominici, Massimo
Morandi, Uliano
Maiorana, Antonino
Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
title Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
title_full Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
title_fullStr Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
title_full_unstemmed Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
title_short Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
title_sort overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007296/
https://www.ncbi.nlm.nih.gov/pubmed/32082488
http://dx.doi.org/10.18632/oncotarget.27472
work_keys_str_mv AT araminibeatrice overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT banchellifederico overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT bettellistefania overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT manfredinisamantha overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT damicoroberto overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT mascialevalentina overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT pinellimassimo overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT morettimargherita overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT stefanialessandro overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT bertolinifederica overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT dominicimassimo overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT morandiuliano overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy
AT maioranaantonino overallsurvivalinpatientswithlungadenocarcinomaharboringnichemutationsanobservationalstudy